Fig. 6

Analysis of the SARS-CoV-2 growth in hiPSC-derived lung organoids treated with tobramycin or sisomicin. (a) A schematic representation of the protocol for infection assay using hiPSC-derived lung organoids infected with SARS-CoV-2 B.1.617.2 (Delta) or BA.1 (Omicron) variants. (b) Cell viability in non-infected hiPSC-derived lung organoids treated without (Mock) or with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) (n = 3 each) was assessed using the WST-8 assay. Data are presented as mean ± SEM and are representative of three independent experiments. (c, d) The viral copy number in the culture supernatant of hiPSC-derived lung organoids treated with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) (n = 3 each) in combination with infection by the SARS-CoV-2 Delta (c) or Omicron (d) variants were measured by RT-qPCR. “Mock” indicates uninfected and untreated control samples. Data are presented as mean ± SEM and are representative of three independent experiments. p = 0.053, p = 0.088, and ***p < 0.001 indicates significant differences compared to the Water-treated infected group, as determined by one-way ANOVA followed by Dunnett’s post hoc test. Results were reproducible through these experiments.